



18th January 2013

Aurobindo Pharma receives final approvals for Felodipine Extended-release Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg. (ANDA 203417).

Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg is the generic equivalent of AstraZeneca's Plendil® Extended-release Tablets, 2.5mg, 5mg and 10mg and indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. The annual sale of the product is approximately US\$ 64 million for the twelve months ending March 2012 according to IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 172 ANDA approvals (147 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com